Comparative Effectiveness of Outpatient COVID‐19 Therapies in Solid Organ Transplant Recipients
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.14436 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Zachary A Yetmar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Organ Transplantation, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Mayo Clinic.
Abstract (Originalsprache)
Background
Multiple outpatient therapies have been developed for COVID‐19 in high‐risk individuals, but solid organ transplant (SOT) recipients were not well represented in controlled clinical trials. To date, few comparative studies have evaluated outcomes between outpatient therapies in this population.
Methods
We performed a retrospective cohort study using de‐identified administrative claims data from OptumLabs Data Warehouse. Patients were included if they were age ≥ 18 years, diagnosed with COVID‐19 between January 2022 and December 2023, and underwent SOT prior to COVID‐19. The primary outcome was 30‐day hospitalization. Stabilized inverse probability of treatment weighting was used to account for potential confounding variables.
Results
4192 SOT recipients with COVID‐19 were identified. 1403 received an outpatient COVID‐19 therapy, including anti‐spike monoclonal antibodies ( N = 748, 53.3%), molnupiravir ( N = 327, 23.3%), ritonavir‐boosted nirmatrelvir ( N = 217, 15.5%), or remdesivir ( N = 141, 10.0%). In weighted analysis compared to no treatment, anti‐spike monoclonal antibodies (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.28–0.55; p < 0.001), molnupiravir (HR 0.56, 95% CI 0.36–0.89; p = 0.013), and nirmatrelvir (HR 0.47, 95% CI 0.25–0.89; p = 0.020) were associated with reduced hospitalization risk, while remdesivir (HR 1.00, 95% CI 0.50–1.98; p = 0.992) was not. Hospitalization rates were similar between the treatment agents, apart from remdesivir showing a higher risk compared to anti‐spike monoclonal antibodies.
Conclusions
Outpatient COVID‐19 therapies were largely associated with improved outcomes among SOT recipients. These treatment agents showed similar rates of 30‐day hospitalization, except for remdesivir. The choice of outpatient COVID‐19 therapy in SOT recipients should primarily account for patients’ individual circumstances and drug‐drug interactions rather than differential therapeutic efficacy. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio, USA.
- Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA.
- OptumLabs, Eden Prairie, Minnesota, USA.
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Zachary A Yetmar, Kelly M Pennington, Raymund R Razonable
Förderung
- Mayo Clinic
Zitieren
APA
Yetmar, Z. A., Thao, V., Helfinstine, D. A., Pennington, K. M., & Razonable, R. R. (2025). Comparative Effectiveness of Outpatient COVID‐19 Therapies in Solid Organ Transplant Recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14436
Vancouver
Yetmar ZA, Thao V, Helfinstine DA, Pennington KM, Razonable RR. Comparative Effectiveness of Outpatient COVID‐19 Therapies in Solid Organ Transplant Recipients. Transplant Infectious Disease. 2025. doi:10.1111/tid.14436
BibTeX
@article{Yetmar2025,
author = {Yetmar, Zachary A and Thao, Viengneesee and Helfinstine, David A and Pennington, Kelly M and Razonable, Raymund R},
title = {Comparative Effectiveness of Outpatient COVID‐19 Therapies in Solid Organ Transplant Recipients},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.14436}
}
EUVIMED